ATE394396T1 - Triazolderivate als faktor-xa-inhibitoren - Google Patents

Triazolderivate als faktor-xa-inhibitoren

Info

Publication number
ATE394396T1
ATE394396T1 AT04731152T AT04731152T ATE394396T1 AT E394396 T1 ATE394396 T1 AT E394396T1 AT 04731152 T AT04731152 T AT 04731152T AT 04731152 T AT04731152 T AT 04731152T AT E394396 T1 ATE394396 T1 AT E394396T1
Authority
AT
Austria
Prior art keywords
factor
compounds
formulae
chem
factor viia
Prior art date
Application number
AT04731152T
Other languages
English (en)
Inventor
Marc Nazare
Volker Laux
Armin Bauer
Michael Wagner
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of ATE394396T1 publication Critical patent/ATE394396T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT04731152T 2003-05-19 2004-05-05 Triazolderivate als faktor-xa-inhibitoren ATE394396T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03011309A EP1479679A1 (de) 2003-05-19 2003-05-19 Triazolderivate als Faktor-Xa-Inhibitoren

Publications (1)

Publication Number Publication Date
ATE394396T1 true ATE394396T1 (de) 2008-05-15

Family

ID=33040956

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04731152T ATE394396T1 (de) 2003-05-19 2004-05-05 Triazolderivate als faktor-xa-inhibitoren

Country Status (12)

Country Link
EP (2) EP1479679A1 (de)
JP (1) JP4608495B2 (de)
AT (1) ATE394396T1 (de)
AU (1) AU2004238498B2 (de)
BR (1) BRPI0410763A (de)
CA (1) CA2526082C (de)
DE (1) DE602004013577D1 (de)
IL (1) IL171843A (de)
MX (1) MXPA05012058A (de)
PE (1) PE20050154A1 (de)
TW (1) TW200503694A (de)
WO (1) WO2004101555A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
ATE557010T1 (de) * 2006-03-24 2012-05-15 Eisai R&D Man Co Ltd Triazolonderivat
SG187396A1 (en) * 2007-07-19 2013-02-28 Lundbeck & Co As H 5-membered heterocyclic amides and related compounds
EP2202231A4 (de) 2007-09-21 2011-09-28 Eisai R&D Man Co Ltd 2,3-dihydroiminoisoindolderivate
EP2560966B1 (de) 2010-03-30 2021-01-06 Verseon International Corporation Mehrfach substituierte aromatische verbindungen als thrombinhemmer
EP2970141B1 (de) * 2013-03-15 2020-02-26 Verseon Corporation Halogenpyrazole als thrombinhemmer
ES2853483T3 (es) 2013-03-15 2021-09-16 Verseon Int Corporation Compuestos aromáticos multisustituidos como inhibidores de la serina proteasa
RS63108B1 (sr) 2013-03-15 2022-04-29 Cyclerion Therapeutics Inc Sgc stimulatori
BR112017004704A2 (pt) 2014-09-17 2018-01-23 Verseon Corp composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
US10532995B2 (en) 2015-02-27 2020-01-14 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
US11724997B2 (en) 2018-03-01 2023-08-15 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
WO1999032454A1 (en) * 1997-12-22 1999-07-01 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
WO2001032628A1 (en) * 1999-11-03 2001-05-10 Bristol-Myers Squibb Pharma Company Cyano compounds as factor xa inhibitors
AU2001273040A1 (en) * 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors

Also Published As

Publication number Publication date
MXPA05012058A (es) 2006-06-23
EP1479679A1 (de) 2004-11-24
EP1628971A1 (de) 2006-03-01
BRPI0410763A (pt) 2006-08-01
AU2004238498B2 (en) 2010-07-22
IL171843A (en) 2010-12-30
DE602004013577D1 (de) 2008-06-19
CA2526082C (en) 2012-07-24
CA2526082A1 (en) 2004-11-25
AU2004238498A1 (en) 2004-11-25
TW200503694A (en) 2005-02-01
PE20050154A1 (es) 2005-04-29
WO2004101555A1 (en) 2004-11-25
JP4608495B2 (ja) 2011-01-12
JP2006528941A (ja) 2006-12-28
EP1628971B1 (de) 2008-05-07

Similar Documents

Publication Publication Date Title
DE602004028367D1 (de) Neue indolderivate als faktor xa-inhibitoren
ATE429432T1 (de) Indazolderivate als faktor xa-inhibitoren
ATE293617T1 (de) Oxybenzamidderivate als faktor-xa-inhibitoren
WO2003044014A8 (en) Indole-2-carboxamides as factor xa inhibitors
TW200505914A (en) Pyrazole-derivatives as factor Xa inhibitors
WO2005085239A3 (en) PYRROLE-DERIVATIVES AS FACTOR Xa INHIBITORS
NO20025810D0 (no) Faktor VIIA-inhibitoriske (tio)ureaderivater, deres fremstilling og anvendelse
DK1423357T3 (da) Urinstofderivater med antiproteolytisk aktivitet
YU29702A (sh) N-gvanidinoalkilamidi, njihovo dobijanje, njihova primena i farmaceutski preparati koji ih obuhvataju
ATE394396T1 (de) Triazolderivate als faktor-xa-inhibitoren
TW200504027A (en) Imidazole-derivatives as factor Xa inhibitors
TNSN05297A1 (en) BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
TNSN05296A1 (en) AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
TW200716620A (en) Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitors
JO2467B1 (en) New indole derivatives as an inhibitor of Xa

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties